The human rotavirus vaccine Rotarix™ in infants: an integrated analysis of safety and reactogenicity

Area of Science:

• Vaccinology
• Pediatric Infectious Diseases
• Clinical Pharmacology

Background:

• Rotavirus is a leading cause of severe diarrheal disease in infants globally.
• Live-attenuated rotavirus vaccines have been developed to prevent rotavirus gastroenteritis.
• Assessing the safety and reactogenicity of rotavirus vaccines is crucial for public health.

Purpose of the Study:

• To conduct an integrated analysis of safety and reactogenicity data for the oral live-attenuated human rotavirus vaccine, Rotarix™.
• To compare adverse events, serious adverse events, and intussusception rates between infants receiving Rotarix™ and placebo.

Main Methods:

• Analysis of 28 randomized, placebo-controlled, double-blind Phase II and III trials involving over 100,000 infants.
• Inclusion of infants aged 6-20 weeks receiving 2 or 3 doses of vaccine or placebo.
• Systematic recording and evaluation of solicited adverse events, unsolicited adverse events, serious adverse events, and deaths.

Main Results:

• The incidence of solicited and unsolicited adverse events of any or Grade 3 severity was similar between the vaccine and placebo groups.
• A significantly lower proportion of serious adverse events (SAEs) were reported in the vaccine group compared to the placebo group (RR=0.9; P=0.01).
• Rates of death and intussusception were low and similar between the vaccine and placebo groups.

Conclusions:

• The oral live-attenuated human rotavirus vaccine, Rotarix™, exhibits a safety and reactogenicity profile similar to placebo.
• The findings support the favorable safety profile of Rotarix™ in infants.
• Integrated safety data from large-scale clinical trials provide robust evidence for vaccine safety evaluation.